IBONYSEPharmaceutical PreparationsFiscal year ends December 31

IMPACT BIOMEDICAL INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$3.06+0.38 (+14.18%)

Close on Oct 19, 2026

Market cap: $329.93M
P/E (TTM): –
Dividend yield: –

IMPACT BIOMEDICAL INC. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Revenue	0.03	–	–	0.05
Cost of Revenue	0.42	–	–	–
Gross Profit	-0.39	–	–	–
Research & Development	0.34	0.28	1.69	1.23
Selling, General & Admin	0.87	0.72	0.32	0.33
Selling & Marketing	0.02	0.63	0.07	–
Operating Expenses	–	29	4.03	–
Total Costs & Expenses	–	–	4.03	3.45
Operating Income	-4.28	-29	-4.03	-3.40
Interest Expense	0.79	1.07	0.44	0.46
Interest & Investment Income	–	–	0.01	0.02
Asset Impairment Charges	–	25	0	0
Gain (Loss) on Sale of Assets	-0.01	–	–	–
Pretax Income	-14	-25	-4.41	-7.88
Income Tax Expense	-2.58	0.03	–	-0.62
Net Income incl. Noncontrolling Interests	-12	-25	-4.41	–
Minority Interest in Earnings	-0.03	-0.06	-0.07	–
Net Income	-12	-25	-4.34	-7.26
Net Income to Common	–	–	-4.34	-7.05
EPS (Basic)(per share)	-0.38	-2.30	-0.07	-0.10
EPS (Diluted)(per share)	-0.38	-2.30	-0.07	-0.10
Shares Outstanding (Basic, Weighted)(shares)	32	11	60	70
Shares Outstanding (Diluted, Weighted)(shares)	32	11	60	70
EBITDA	-3.14	-28	-2.91	-2.29

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: -1120.0%
Operating margin: -14597.1%
Net margin: 2254.3%
Return on equity, FY2025: -142.9%

Financial strength

Current ratio: 0.16
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.5%

Valuation

P/E ratio: –
Price to sales: 9426.66
Price to book: 30.65
Dividend yield: –